Search

Ralf Gutzmer

Early versus late response to PD-1-based immunotherapy in metastatic melanoma
Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- (“Triple”) wild type melanomas
Adjuvant treatment and outcome of stage III melanoma patients: Results of a multicenter real-world German Dermatologic Cooperative Oncology Group (DeCOG) study
Characterisation and outcome of RAC1 mutated melanoma

Published with Wowchemy — the free, open source website builder that empowers creators.